Navigation Links
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Date:7/22/2009

st common adverse events greater than or equal to 20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain. Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.

Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule dr
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
2. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
3. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
6. Promising drug combination may help those with ocular melanoma that has spread
7. Combination therapy reverses effects of portal hypertension in rats
8. Combination vaccines okay for infants, study shows
9. Antidepressants and painkillers - a dangerous combination
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products ... Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products International. ... on your goals. Kathleen graduated from Florida State University with a Bachelor ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder ... mission is to increase acceptance of the chiropractic field in the military. All too ... them. Although Chiropractic was made available to the VA program over a decade ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... discount programs has soared in recent months, according to leading pharmacy ... ... -- AIS,s Drug Benefit News -- Demand for Web-based prescription drug ... according to pharmacy executives who point to the weak economy and ...
... 1,300,000 Adults Living in the U.S. with Congenital Heart ... Senator Richard Durbin (D-IL) and Congressman Zack Space ... time in history, will address the needs of those ... common birth defect that affects approximately one out of ...
... the gift of sound to children in needPISCATAWAY, ... one of the largest manufacturers of hearing instruments ... Quota International to provide free hearing instruments to ... Quota International,s Sound Beginnings Program, Siemens will donate ...
... Calif., March 18 Codexis, Inc. today announced that ... Vice President, Corporate Development from his previous position as ... to Alan Shaw, Ph.D., President and CEO. Dr. ... He joined Codexis in 2005 as Corporate Counsel ...
... Medivation, Inc. (Nasdaq: MDVN ) today ... the U.S. Food and Drug Administration (FDA) to ... its novel androgen receptor antagonist, in patients with ... docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial ...
... usually smaller and more contained, study finds , , WEDNESDAY, March ... can reduce the risk of death by as much as ... at information on 1,044 women who were seen at a ... who had developed a second breast cancer -- 455 with ...
Cached Medicine News:Health News:Online Rx Price Comparison Tools, Drug Discount Card Use Soars in Weak Economy 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 3Health News:Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International 2Health News:Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International 3Health News:Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International 4Health News:Codexis Names Sarret SVP, Corporate Development 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:When Breast Cancer Recurs, Finding Pre-Symptoms Is Key 2
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... visión holística de l cuidado al ... trayecto   Royal Philips  ... debut europeo de IntelliSpace Cardiovascular , un sistema ... sofisticadas herramientas para acceder, analizar y compartir imágenes cardiovasculares ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... DIEGO, Sept. 19, 2011 Marshall Edwards, Inc. (Nasdaq: ... development of novel therapeutics targeting cancer metabolism, announced today that ... clinical trial of its lead drug candidate ME-143 in patients ... the Sarah Cannon Research Institute, is expected to enroll up ...
... (NYSE: LLY ) will bring one of its ... 2011 Annual Legislative Conference presented by the Congressional Black Caucus ... In attendance will be Eli Lilly and Company,s ... C onnected and E mpowered ...
Cached Medicine Technology:Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 4Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference 2
... worlds leading medical technology company and ... for more than a decade, introduces ... The ACT Plus System is a ... determine coagulation endpoints in whole blood, ...
An Innovative New System to Help You Meet the Challenges of Anterior Spine Surgery...
... the Alcon OcuScan RxP Ophthalmic Ultrasound System, ... instrumentation. With improved auto modes and flexible ... to obtain measurements that are both accurate ... by providing high quality eye measurements in ...
... the Atlas+ HF ICD is designed to provide ... and quality of life. The Atlas+ HF ICD ... resynchronization therapy (CRT), and it packs its power ... physiologic-shaped can. In addition to its high energy, ...
Medicine Products: